The impact of the 13-valent pneumococcal conjugate vaccine on pneumococcal carriage in the Community Acquired Pneumonia Immunization Trial in Adults (CAPiTA) Study

Clinical Infectious Diseases Jan 11, 2018

van Deursen AMM, et al. - Researchers here examined the direct effects of the 13-valent pneumococcal conjugate vaccine (PCV13) in community dwelling older adults as part of the randomized controlled Community Acquired Pneumonia immunization Trial in Adults (CAPiTA). In this work, a single dose of PCV13 seemed to elicit a small and temporary reduction in vaccine-type (VT)-carriage at 6 months post-vaccination in community-dwelling adults of 65 years and older. They recognized neither replacement by non-vaccine serotypes nor impact on other nasopharyngeal bacteria.
Go to Original

Sign-up to continue reading. It is free & takes less than 2 mins

  • 45 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Free & unlimited access to original articles and quizzes
  • Nonloggedinlock icon
    Secure: we never sell your data
This article is only available to members. Are you a doctor? Click here to signup for free.
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay